Seat­tle Ge­net­ics de­tails pos­i­tive OS and PFS da­ta for tu­ca­tinib in breast can­cer

Seat­tle Ge­net­ics $SGEN is show­ing off more pos­i­tive da­ta around tu­ca­tinib, its piv­otal-stage drug for HER2 pos­i­tive breast can­cer.

A month af­ter hear­ing about solid­ly up­beat haz­ard ra­tios, we learned to­day that the es­ti­mat­ed pro­gres­sion-free sur­vival rate at one year was 33% in the tu­ca­tinib arm com­pared to 12% for pa­tients tak­ing trastuzum­ab and capecitabine alone.

Me­di­an PFS was 7.8 months (95% CI: 7.5, 9.6) in the tu­ca­tinib arm, com­pared to 5.6 months (95% CI: 4.2, 7.1) in the con­trol arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER